Homepage | CIDRAP
WEBThe Influenza Vaccines Roadmap provides a much-needed framework for organizing the efforts of existing influenza researchers while identifying a wide range of opportunities that will encourage new investigators to join the work.
COVID-19 - CIDRAP
WEBNew report: COVID more severe, longer-lasting than other respiratory diseases. COVID-19 participants most often reported fatigue, muscle aches, headache, and loss of taste and/or smell, consistent with the more extensive systemic COVID-19 effects. Mary Van Beusekom.
Infectious Disease Topics A-Z - CIDRAP
WEBA comprehensive list of infectious diseases that CIDRAP covers. Our site is an authoritative, reliable, and timely source of science-based information about global, emerging infectious diseases.
Osterholm Update - CIDRAP
WEBSep 5, 2024 · May 30, 2024. In "An Unfolding Saga," Dr. Osterholm and Chris Dall discuss the latest H5N1, COVID-19, and measles news. Dr. Osterholm also answers an ID query on influenza and shares the latest "This Week in Public Health History" segment. Study confirms infection in mice fed H5N1-contaminated raw milk (CIDRAP News)
About CIDRAP | CIDRAP
WEBThe Center for Infectious Disease Research and Policy (CIDRAP; "SID-wrap") is a global leader in addressing public health preparedness and emerging infectious disease response. Founded in 2001, CIDRAP is part of the Research and Innovation Office at the University of Minnesota. CIDRAP works to prevent illness and death from targeted infectious ...
Evidence growing for COVID antivirals to cut poor outcomes
WEB18 hours ago · A recently published systematic review and meta-analysis found no evidence that the antiviral drugs nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Lagevrio) help prevent COVID-19 hospitalization, death, or persistent symptoms, results that the authors say call for reassessment of the role that oral antivirals play in the context of currently circulating SARS-CoV-2 variants and population ...
Pneumonia - CIDRAP
WEBOmadacycline post-marketing study adds evidence for use in treating pneumonia. Approved in 2018 for treating pneumonia and skin infections, the drug has shown activity against both gram-positive and gram-negative bacteria, including …
CIDRAP in the News
WEBAug 15, 2024 In Foreign Affairs, Director Michael Osterholm, PhD, MPH, and coauthor Mark Olshaker discuss how governments and international organizations have done far too little to prepare for the next pandemic-causing virus.. Jul 2, 2024 CIDRAP releases two new Research and Development Roadmaps: one for developing tools to combat Nipah virus and the other for tools to combat Lassa fever.
COVID-19: CIDRAP Commentaries
WEBCOVID-19: The CIDRAP Viewpoint. Starting at the beginning of the pandemic, CIDRAP compiled a groundbreaking of series of reports on key aspects of COVID-19, such as what direction the pandemic might take, how to communicate risks effectively, smart testing for the virus and for antibodies to it, contact tracing, surveillance, ensuring a ...
COVID-19: The CIDRAP Viewpoint
WEBApr 30, 2020 · Part 1: The Future of the COVID-19 Pandemic: Lessons Learned from Pandemic Influenza. Kristine A. Moore, MD, MPH; Marc Lipsitch, DPhil; John M. Barry, MA; Michael T ...